1. Chang Y, Guo H, Li X, Zong L, Wei J, Li Z, Luo C, Yang X, Fang H, Kong X*,Hou X*. Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity.J Med Chem.2024, 67(18):16480-16504.
2. Liu M, Gao S, Wang Y, Yang X, Fang H*,Hou X*. Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death.J Med Chem. 2024, 67(17):15098-15117.
3. Liu M, Gao S, Liang T, Qiu X, Yang X, Fang H*,Hou X*. Discovery of Novel Src Homology-2 Domain-ContainingPhosphatase2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.J. Med. Chem.2022, 65(18):12200-12218.
4. Chen C, Li X, Zhao H, Liu M, Du J, Zhang J, Yang X,Hou X*, Fang H*. Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.J. Med. Chem.2022, 65(4):3667-3683.
5. Jin X#,Hou X#, Wang X, Zhang M, Chen J, Song M, Zhang J, Zheng H, Chang W, Lou H. Characterization of an allosteric inhibitor of fungal-specific C-24 sterol methyltransferase to treat Candida albicans infections.Cell Chem Biol.2023, 30(5):553-568.e7.
6. Chang Y, Li X, Zhou Y, Yang X, Zhao W*, Fang H*,Hou X*. Simultaneous inhibition of FLT3 and HDAC by novel 6-ethylpyrazine-2-Carboxamide derivatives provides therapeutic advantages in acute myelocytic leukemia.Eur J Med Chem.2024, 279:116847.
7. Liang X, Zhao H, Du J, Li X, Li K, Zhao Z, Bi W, Zhang X, Yu D, Zhang J, Fang H*,Hou X*. Discovery of benzofuran-2-carboxylic acid derivatives as lymphoid tyrosine phosphatase (LYP) inhibitors for cancer immunotherapy.Eur J Med Chem.2023, 258:115599.
8. Liang T, Wang F, Elhassan RM, Cheng Y, Tang X, Chen W*, Fang H*,Hou X*.Targeting histone deacetylases for cancer therapy: Trends and challenges.Acta Pharm Sin B. 2023, 13(6):2425-2463.
9. Zhao Z, Du J, Du Y, Gao Y, Yu M, Zhang Y*, Fang H*,Hou X*. Deciphering the Allosteric Activation Mechanism of SIRT6 Using Molecular Dynamics Simulations.J Chem Inf Model.2023, 63(18):5896-5902.
10. Elhassan RM,Hou X*, Fang H*. Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug discovery.Med. Res. Rev.2022, 42(3):1064-1110.
11. Liu M, Gao S, Elhassan RM,Hou X*, Fang H*. Strategies to overcome drug resistance using SHP2 inhibitors.Acta Pharm. Sin. B. 2021,11(12):3908-3924.
12.Hou X, et al. Inhibition of striatal-enriched protein tyrosine phosphatase by targeting computationally revealed cryptic pockets,Eur. J. Med. Chem., 2020,190:112131.
13. Liu L, Liu R, Yang X,Hou X*, Fang H*. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.Eur. J. Med. Chem.,2020, 191:112142.
14. Chen C, Yang X, Fang H*,Hou X*. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.Eur. J. Med. Chem.2019, 181:111563.
15. Li K#,Hou X#, Li R#, Bi W#, Yang F, Chen X, Xiao P, Liu T, Lu T, Zhou Y, Tian Z, Shen Y, Zhang Y, Wang J, Fang H, Sun J*, Yu X.* Identification and structure-function analyses of an allosteric inhibitor of the tyrosine phosphatase PTPN22.J. Biol. Chem.2019, 294(21):8653-8663.